Press Releases

Month Year

Get News Alerts by Email

Nov 27, 2024

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
Nov 21, 2024

EISAI SUPPORTS SLEEP RESEARCH SOCIETY FOUNDATION EDUCATIONAL WEBINAR: LESSONS LEARNED FROM CENTRAL DISORDERS OF HYPERSOMNOLENCE AND FUTURE DIRECTIONS

Eisai Inc. announced today its sponsorship of the upcoming webinar, "Lessons Learned from Central Disorders of Hypersomnolence and Future Directions", a key educational event from the Sleep...
Nov 14, 2024

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
Oct 31, 2024

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
Oct 30, 2024

EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)

-Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease- TOKYO, Oct. 30, 2024 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today...

Show per page

Open a printable version of this page
Email the URL of this page to a friend

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa